PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1

Terminated

Conditions: Neoplasm Metastasis

Interventions: Drug: PF-07265807
Drug: Sasanlimab
Drug: Axitinib

First Posted Date: 2020-07-07

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 88

Registration Number: NCT04458259

Locations: 🇺🇸
Henry Eye Clinic, Fayetteville, Arkansas, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
UCI Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 24 locations

Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer

Phase 1

Completed

Conditions: Neurogenic Detrusor Overactivity

Interventions: Drug: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
Drug: Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B)
Drug: Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B)
Drug: Fesoterodine BIC SR4 fed (Treatment E in Part B)
Drug: Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A)

First Posted Date: 2020-07-01

Last Posted Date: 2021-02-10

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT04452838

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed

Conditions: Major Depression

Interventions: Drug: Desvenlafaxine
Drug: Escitalopram
Drug: Paroxetine
Drug: Fluoxetine
Drug: Mirtazapine
Drug: Duloxetine
Drug: Sertraline
Drug: Venlafaxine
Drug: Tianeptine
Drug: Vortioxetine
Drug: Bupropion

First Posted Date: 2020-06-24

Last Posted Date: 2024-12-09

Lead Sponsor: Pfizer

Target Recruit Count: 370212

Registration Number: NCT04446039

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

Phase 2

Completed

Conditions: Meningococcal Vaccine

Interventions: Biological: MenABCWY
Biological: Saline

First Posted Date: 2020-06-19

Last Posted Date: 2025-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 309

Registration Number: NCT04440176

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC, South Jordan, Utah, United States
🇺🇸
California Research Foundation, San Diego, California, United States
🇺🇸
Nona Pediatric Center, Orlando, Florida, United States

and more 13 locations

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

Phase 3

Completed

Conditions: Meningococcal Vaccine

Interventions: Biological: MenABCWY
Biological: Trumenba
Biological: Saline
Biological: MenACWY-CRM

First Posted Date: 2020-06-19

Last Posted Date: 2023-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 2431

Registration Number: NCT04440163

Locations: 🇺🇸
Fiel Family and Sports Medicine, PC/CCT Research, Tempe, Arizona, United States
🇺🇸
San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States
🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States

and more 70 locations

Treatment Resistance Following Anti-cancer Therapies

Not Applicable

Terminated

Conditions: Disease Progression

Interventions: Procedure: De novo tumor tissue biopsy
Procedure: Research blood draws

First Posted Date: 2020-06-17

Last Posted Date: 2024-12-03

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT04436120

Locations: 🇺🇸
Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States
🇦🇷
Clínica Viedma S.A., Viedma, RIO Negro, Argentina
🇦🇷
Sanatorio de la Mujer, Rosario, Santa FÉ, Argentina

and more 26 locations

Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2020-06-17

Last Posted Date: 2023-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 109

Registration Number: NCT04435769

Locations: 🇨🇿
Fakultní nemocnice Motol, Praha 5, Czechia

Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Enbrel

First Posted Date: 2020-06-11

Last Posted Date: 2021-09-09

Lead Sponsor: Pfizer

Target Recruit Count: 1493

Registration Number: NCT04428424

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

Global Prevalence of ATTR-CM in Participants With HFpEF

Not Applicable

Terminated

Conditions: Heart Failure With Preserved Ejection Fraction
Transthyretin Amyloid Cardiomyopathy

Interventions: Diagnostic Test: Scintigraphy

First Posted Date: 2020-06-11

Last Posted Date: 2024-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 347

Registration Number: NCT04424914

Locations: 🇺🇸
Advance Medical Research Center, Miami, Florida, United States
🇺🇸
Bioclinical Research Alliance Inc., Miami, Florida, United States
🇺🇸
Biogenix Molecular, Miami, Florida, United States

and more 47 locations

Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Enbrel

First Posted Date: 2020-06-11

Last Posted Date: 2021-10-25

Lead Sponsor: Pfizer

Target Recruit Count: 486

Registration Number: NCT04428411

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy